More recently, on October 22, 2024, Novo Nordisk, the creator of the Ozempic (semaglutide) and Wegovy (semaglutide) injections, nominated its semaglutide glucagon-like peptide 1 (GLP-1) medications to be listed
However, clinicians should remain vigilant for signs of excessive metabolic suppression or thyroid dysfunction, particularly in patients with pre-existing thyroid conditions or those experiencing symptoms beyond cold intolerance, such as severe fatigue, hair loss, or cognitive changes that might suggest thyroid hormone imbalance requiring investigation
Time the switch to allow approval before stopping the current drug if continuity matters
Standard oral glutathione requires stricter empty-stomach timing due to poor bioavailability
[Science] 24
This is mainly due to the growing consumption of GLP-1 drugs for diabetes management and a strong pipeline further supporting growth